Merck’s Frazier Optimistic About Pipeline Future
This article was originally published in The Pink Sheet Daily
Merck’s Ken Frazier spoke about his faith in anaceptrapib, despite the recent failure of Tredaptive, at the recent Goldman Sachs Conference. He also addressed Merck’s pipeline and consolidation in the industry.
You may also be interested in...
Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.
A brief mention in an SEC filing revealed that Merck has ceased the development of a combination cholesterol pill; the once hot ‘0524 program had languished in late-stages for several years.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.